Yes, I understand. But 40% had success in partner group and 75% in launch, both have high odd, yeah so you would think the partner would have a higher percent successful with the easy sales. We would have to look more, but I bet most of these needed money, that is common in most prerevenue biotech, not just a Cydy problem.

I will look up the US study. The point though, I hear a lot of concerns going alone, but the data I have seen seems to indicate the opposite. Probably a lot of these failures in the partner group got bad deals. And in the launch group, people will give antidotal evidence, xyz went it alone and failed, but I look up the xyz drug and it is a vaccine for hep b. Well I could have told you that was going to fail with or without a partner. I believe leronlimab is a superior product to what is on the market, which will help greatly. No SAEs in over 800 patients, no resistance even in mdr4 patients, once a week dosing, unmet need (which would have gotten odd if not for mono), very easy sell to MDs I believe.